BridgeBio Pharma Inc. [NASDAQ: BBIO] surged by $2.9 during the normal trading session on Monday and reaching a high of $36.90 during the day while it closed the day at $36.46. The company report on September 3, 2020 that BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on September 1, 2020, the compensation committee of BridgeBio’s board of directors granted 10 new employees options to purchase an aggregate of 18,231 shares of the Company’s common stock with a per share exercise price of $27.62 and restricted stock units for an aggregate of 19,915 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019.
BridgeBio Pharma Inc. stock has also gained 26.07% of its value over the past 7 days. However, BBIO stock has inclined by 17.20% in the 3 months of the year. Over the past six months meanwhile, it has gained 106.57% and gained 4.02% year-on date.
The market cap for BBIO stock reached $4.40 billion, with 117.01 million shares outstanding and 70.03 million shares in the current float. Compared to the average trading volume of 578.92K shares, BBIO reached a trading volume of 1129076 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BridgeBio Pharma Inc. [BBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $44.45 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA/Merrill have made an estimate for BridgeBio Pharma Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 25, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on May 19, 2020, representing the official price target for BridgeBio Pharma Inc. stock. Previously, the target price had yet another raise to $50, while H.C. Wainwright analysts kept a Buy rating on BBIO stock.
The Average True Range (ATR) for BridgeBio Pharma Inc. is set at 1.79, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 108.35. The Price to Book ratio for the last quarter was 16.06, with the Price to Cash per share for the same quarter was set at 6.97.
BBIO stock trade performance evaluation
BridgeBio Pharma Inc. [BBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.07. With this latest performance, BBIO shares gained by 25.25% in over the last four-week period, additionally plugging by 106.57% over the last 6 months – not to mention a rise of 40.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 75.03, with the RSI for the last a single of trading hit 83.16, and the three-weeks RSI is set at 68.65 for BridgeBio Pharma Inc. [BBIO]. The present Moving Average for the last 50 days of trading for this stock 29.89, while it was recorded at 33.67 for the last single week of trading, and 31.14 for the last 200 days.
BridgeBio Pharma Inc. [BBIO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc. [BBIO] shares currently have an operating margin of -656.41 and a Gross Margin at +93.84. BridgeBio Pharma Inc.’s Net Margin is presently recorded at -642.47.
Return on Total Capital for BBIO is now -52.84, given the latest momentum, and Return on Invested Capital for the company is -59.93. Return on Equity for this stock declined to -213.19, with Return on Assets sitting at -47.53. When it comes to the capital structure of this company, BridgeBio Pharma Inc. [BBIO] has a Total Debt to Total Equity ratio set at 24.43. Additionally, BBIO Total Debt to Total Capital is recorded at 19.63, with Total Debt to Total Assets ending up at 15.80. Long-Term Debt to Equity for the company is recorded at 22.47, with the Long-Term Debt to Total Capital now at 18.06.
Reflecting on the efficiency of the workforce at the company, BridgeBio Pharma Inc. [BBIO] managed to generate an average of -$1,050,754 per employee.BridgeBio Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.
Earnings per share (EPS) analysis for BridgeBio Pharma Inc. [BBIO] stock
With the latest financial reports released by the company, BridgeBio Pharma Inc. posted -0.51/share EPS, while the average EPS was predicted by analysts to be reported at -0.55/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BBIO.
BridgeBio Pharma Inc. [BBIO]: Insider Ownership positions
There are presently around $4,278 million, or 96.07% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 34,510,971, which is approximately -6.476% of the company’s market cap and around 6.50% of the total institutional ownership; VIKING GLOBAL INVESTORS LP, holding 26,620,991 shares of the stock with an approximate value of $970.6 million in BBIO stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $244.51 million in BBIO stock with ownership of nearly 0% of the company’s market capitalization.
Positions in BridgeBio Pharma Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 81 institutional holders increased their position in BridgeBio Pharma Inc. [NASDAQ:BBIO] by around 8,594,814 shares. Additionally, 35 investors decreased positions by around 4,278,399 shares, while 17 investors held positions by with 104,471,204 shares. The mentioned changes placed institutional holdings at 117,344,417 shares, according to the latest SEC report filing. BBIO stock had 33 new institutional investments in for a total of 1,124,384 shares, while 11 institutional investors sold positions of 471,344 shares during the same period.